The systematic review and meta-analysis published by Liu et al. summarizes existing evidence and suggests potential metabolic benefits of treatment with polyunsaturated fatty acids (PUFA) in pregnant women with gestational diabetes. According to the findings of this study, treatment with PUFA is able to decrease fasting plasma glucose (FPG) and fasting insulin levels and improves insulin resistance, with a positive effect also on inflammation and a number of lipid fractions, including triglycerides and very-low density lipoprotein cholesterol. These promising results can be reached in the included clinical studies with PUFA daily dose up to 2000 mg, that are very high dosages of PUFA for which human teratogenic risk has not been proven nor has it been ruled out. This is of course a critical issue that should be always considered when evaluating findings from clinical trials involving pregnant women, mainly due to the difficulties of assessing the drugassociated risk of teratogenesis.

PUFA treatment in patients with gestational diabetes mellitus: Lights and shadows / Fogacci F, Rizzo M, Cicero AFG. - In: JOURNAL OF DIABETES AND ITS COMPLICATIONS. - ISSN 1056-8727. - STAMPA. - 37:8(2023), pp. 1-2. [10.1016/j.jdiacomp.2023.108526]

PUFA treatment in patients with gestational diabetes mellitus: Lights and shadows

Cicero AFG
Ultimo
Supervision
2023

Abstract

The systematic review and meta-analysis published by Liu et al. summarizes existing evidence and suggests potential metabolic benefits of treatment with polyunsaturated fatty acids (PUFA) in pregnant women with gestational diabetes. According to the findings of this study, treatment with PUFA is able to decrease fasting plasma glucose (FPG) and fasting insulin levels and improves insulin resistance, with a positive effect also on inflammation and a number of lipid fractions, including triglycerides and very-low density lipoprotein cholesterol. These promising results can be reached in the included clinical studies with PUFA daily dose up to 2000 mg, that are very high dosages of PUFA for which human teratogenic risk has not been proven nor has it been ruled out. This is of course a critical issue that should be always considered when evaluating findings from clinical trials involving pregnant women, mainly due to the difficulties of assessing the drugassociated risk of teratogenesis.
2023
PUFA treatment in patients with gestational diabetes mellitus: Lights and shadows / Fogacci F, Rizzo M, Cicero AFG. - In: JOURNAL OF DIABETES AND ITS COMPLICATIONS. - ISSN 1056-8727. - STAMPA. - 37:8(2023), pp. 1-2. [10.1016/j.jdiacomp.2023.108526]
Fogacci F, Rizzo M, Cicero AFG
File in questo prodotto:
File Dimensione Formato  
Fogacci F_ PUFA treatment_J Diabetes Complications.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 277.64 kB
Formato Adobe PDF
277.64 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/953915
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact